DDInter381 DDInter1480
Cinacalcet is a calcimimetic sold by Amgen under the trade name Sensipar® in North America and Australia and as Mimpara® in Europe. It is used to treat hyperparathyroidism due to parathyroid tumours or renal failure.
Pitolisant is a selective antagonist or inverse agonist of the histamine H3 receptor used to treat type 1 or 2 narcolepsy. Narcolepsy is a chronic neurological disorder that affects 1 in 2,000 individuals and is characterized by excessive daytime sleepiness, abnormal REM sleep manifestations, sleep paralysis and hypnagogic hallucinations. About 60-70% of patients with narcolepsy experience cataplexy, which is a sudden loss of muscle tone triggered by positive or negative emotions. Histaminergic neuron signalling in the brain plays a role in maintaining wakefulness; by blocking histamine autoreceptors, pitolisant enhances the activity of histaminergic neurons, as well as increasing the signalling of other neurotransmitters in the brain. In a European clinical trial of adult patients with narcolepsy, there was a reduction in the Epworth Sleepiness Scale (ESS) score from pitolisant therapy compared to placebo. The therapeutic effectiveness of pitolisant was comparable to that of [modafinil]. Pitolisant therapy was also effective in treating refractory sleepiness in adolescent patients with narcolepsy, where it decreased ESS score and increased the mean sleep onset latency. Adolescent patients with cataplexy also experienced a slight improvement in the frequency and severity of symptoms ; however, the safety of use in adolescent or paediatric patients have not been established with pitolisant. Commonly marketed under the trade name Wakix, oral pitolisant was approved by the EMA in 2016 for the treatment of narcolepsy with or without cataplexy. FDA approved the use of pitolisant in 2019 for excessive daytime sleepiness (EDS) associated with narcolepsy in adults.
Cinacalcet {u} (Compound) resembles {v} (Compound) Dexfenfluramine
Dexfenfluramine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pitolisant
Cinacalcet {u} (Compound) resembles {v} (Compound) Propranolol
Propranolol {u} (Compound) resembles {v} (Compound) Terbinafine
Terbinafine {u} may lead to a major life threatening interaction when taken with {v} Pitolisant
Cinacalcet {u} (Compound) resembles {v} (Compound) Dexfenfluramine
Dexfenfluramine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cobicistat
Cobicistat {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pitolisant
Cinacalcet {u} (Compound) resembles {v} (Compound) Naftifine
Naftifine {u} (Compound) resembles {v} (Compound) Tamoxifen
Tamoxifen {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pitolisant
Cinacalcet {u} (Compound) resembles {v} (Compound) Dexfenfluramine
Dexfenfluramine {u} may lead to a major life threatening interaction when taken with {v} Granisetron
Granisetron {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pitolisant
Cinacalcet {u} (Compound) resembles {v} (Compound) Duloxetine
Duloxetine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Magnesium hydroxide
Magnesium hydroxide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pitolisant
Cinacalcet {u} (Compound) resembles {v} (Compound) Dexfenfluramine
Dexfenfluramine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Repaglinide
Repaglinide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pitolisant
Cinacalcet {u} (Compound) resembles {v} (Compound) Naftifine
Naftifine {u} (Compound) resembles {v} (Compound) Terbinafine
Terbinafine {u} may lead to a major life threatening interaction when taken with {v} Pitolisant
Cinacalcet {u} (Compound) resembles {v} (Compound) Fluoxetine
Fluoxetine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Metronidazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Pitolisant
Cinacalcet {u} (Compound) resembles {v} (Compound) Duloxetine
Duloxetine {u} may lead to a major life threatening interaction when taken with {v} Granisetron
Granisetron {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pitolisant
Cinacalcet (Compound) resembles Dexfenfluramine (Compound) and Dexfenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Pitolisant
Cinacalcet (Compound) resembles Propranolol (Compound) and Propranolol (Compound) resembles Terbinafine (Compound) and Terbinafine may lead to a major life threatening interaction when taken with Pitolisant
Cinacalcet (Compound) resembles Dexfenfluramine (Compound) and Dexfenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Cobicistat and Cobicistat may cause a moderate interaction that could exacerbate diseases when taken with Pitolisant
Cinacalcet (Compound) resembles Naftifine (Compound) and Naftifine (Compound) resembles Tamoxifen (Compound) and Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Pitolisant
Cinacalcet (Compound) resembles Dexfenfluramine (Compound) and Dexfenfluramine may lead to a major life threatening interaction when taken with Granisetron and Granisetron may cause a moderate interaction that could exacerbate diseases when taken with Pitolisant
Cinacalcet (Compound) resembles Duloxetine (Compound) and Duloxetine may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide and Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Pitolisant
Cinacalcet (Compound) resembles Dexfenfluramine (Compound) and Dexfenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Repaglinide and Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Pitolisant
Cinacalcet (Compound) resembles Naftifine (Compound) and Naftifine (Compound) resembles Terbinafine (Compound) and Terbinafine may lead to a major life threatening interaction when taken with Pitolisant
Cinacalcet (Compound) resembles Fluoxetine (Compound) and Fluoxetine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Pitolisant
Cinacalcet (Compound) resembles Duloxetine (Compound) and Duloxetine may lead to a major life threatening interaction when taken with Granisetron and Granisetron may cause a moderate interaction that could exacerbate diseases when taken with Pitolisant